December 18, 2025 Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease Read More
December 18, 2025 Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease Read More
November 20, 2025 Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 Read More
November 12, 2025 Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update Read More
October 9, 2025 Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease Read More
October 6, 2025 Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® Read More
September 23, 2025 Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 Read More
September 18, 2025 Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease Read More
September 4, 2025 Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation Read More
August 12, 2025 Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update Read More
July 15, 2025 Gain Therapeutics Announces New Public Financing Initiative for Clinical Growth Read More
June 30, 2025 Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation Read More
June 10, 2025 Gain Therapeutics Expands Investor Outreach Through Upcoming Conference Participation Read More
May 14, 2025 Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update Read More
May 12, 2025 Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders Read More
April 30, 2025 Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders Read More
April 10, 2025 Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update Read More
March 27, 2025 Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update Read More
March 14, 2025 Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease Read More
February 6, 2025 Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update Read More
February 5, 2025 Gain Therapeutics to Showcase Clinical and Business Progress at Investor Conferences Read More
January 8, 2025 Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 Read More
